Introduction

Venous thromboembolism (VTE) refers to the formation of a blood clot (thrombus) inside veins. The clinically predominant sites of VTE are in the vessels of the leg and the lungs, which result in deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE), respectively. VTE appears in different hospital departments, and has a high risk of inducing medical accidents and tangles [1-3]. However, it is possible to reduce the occurrence of VTE if effective prevention measures are adopted [4]. At present, guidelines have been introduced by different countries and organizations to emphasize the importance of VTE prevention. The World Health Organization (WHO, 2009) has included the prevention of VTE into the surgical safety evaluation criteria [5].

The prerequisite of VTE prevention is to find an effective risk assessment model, which helps screen high risk populations and prevent the occurrence of VTE. In this study, 287 VTE cases were collected and analyzed for risk factors in a Chinese population. The risks of VTE were evaluated using the Caprini and Padua models. Our results indicated that the Caprini model was more effective in evaluating VTE risk among hospitalized patients than the Padua model. As well, the Caprini model was more relevant in VTE risk assessment among surgery patients compared with internal medicine patients, while the Padua model showed no significant differences. In our studies, the most frequent risk factors included obesity, medical patients currently at bed rest, and severe lung disease. Our studies provide clinical support on selecting the suitable risk assessment model of VTE in the Chinese population.

Keywords: Caprini model; Padua model; risk assessment; risk factors; venous thromboembolism
different regional populations. Abundant clinical data are required to help select the appropriate model for specific populations. In this study, 287 VTE cases were collected and analyzed for risk factors in a Chinese population. The risks of VTE were evaluated using the Caprini and Padua models.

2 Materials and Methods

2.1 Patients

387 VTE cases, including both DVT and PTE symptoms, were collected in China Meitan General Hospital and Chaoyang Hospital for a duration of 12 months (Jan 2012 to Dec 2012). DVT was determined by venous color Doppler ultrasonography or venography, while PTE was diagnosed by spiral computed tomography angiography (CTA), pulmonary arteriography (PAG), perfusion scanning or radionuclide pulmonary ventilation. Among the 387 VTE cases, 287 patients who satisfied the following criteria were included in the study: (1) hospitalizations not related to VTE treatment; (2) hospital stay exceeding 2 days; and (3) over 18 years old. Two investigation methods were applied to the selected VTE patients, including a retrospective and follow-up study.

Informed consent: Informed consent has been obtained from all individuals included in this study.

Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has approved by the Institutional Review Board of China Meitan General Hospital and its affiliated Chaoyang Hospital.

2.2 Retrospective Study

Clinical and demographic information, as well as laboratory and imageology examination results were collected for the 287 VTE cases (including name, gender, age, height, weight, hospitalization date, hospitalization department, hospital stay duration, VTE risk factors). Risk factors of VTE were analyzed by the Padua (Table 1) or Caprini model (Table 2). For the Padua model, patients with a cumulative score less than 4 had a low risk of developing VTE; otherwise, they were regarded as high-risk patients. For the Caprini model, the risk levels were defined as follows: (1) Low risk (cumulative risk score 0-1); (2) Moderate risk (cumulative risk score 2); and (3) High risk (cumulative risk score ≥3).

2.3 Follow-up Study

Informed consent forms were signed by all the subjects or their legal guardians. The follow-up lasted between 24 and 36 months (30 months in average). The follow-up items included: (1) re-examination results of VTE after being discharged, e.g. venous color Doppler ultrasonography, venography, spiral CTA, PAG, perfusion scanning and radionuclide pulmonary ventilation; (2) evaluation of whether or not the patient continued to take anti-clotting drugs after leaving the hospitals and the duration thereof;

| Table 1. Risk Assessment of VTE by the Padua Model |
|-----------------------------------------------|
| **Risk factors**                             | **Score** |
| Previous VTE (with the exclusion of superficial vein thrombosis) | 3 |
| Active cancer                                | |
| Reduced mobility                             | |
| Already known thrombophilic condition        | 2 |
| Recent (<1 month) trauma and/or surgery      | |
| Elderly age (>70 years)                      | |
| Heart and/or respiratory failure             | |
| Acute myocardial infarction or ischemic stroke | 1 |
| Obesity (BMI≥30)                              | |
| Acute infection and/or rheumatologic disorder| |
| Ongoing hormonal treatment                   | |

| **Risk factors**                             | **Score** |
|-----------------------------------------------|-----------|
| Previous VTE (with the exclusion of superficial vein thrombosis) | 3 |
| Active cancer                                | |
| Reduced mobility                             | |
| Already known thrombophilic condition        | 2 |
| Recent (<1 month) trauma and/or surgery      | |
| Elderly age (>70 years)                      | |
| Heart and/or respiratory failure             | |
| Acute myocardial infarction or ischemic stroke | 1 |
| Obesity (BMI≥30)                              | |
| Acute infection and/or rheumatologic disorder| |
| Ongoing hormonal treatment                   | |
and (3) outcome of diseases, e.g. disease resolution or recurrence. Of the 287 VTE cases, 260 patients were followed up successfully, because 11 patients died from non-VTE factors and another 16 patients were not able to be contacted during the first follow-up. For the 11 dead patients, 5 of them died from cancer or serious pulmonary infection within the first year of follow-up, and 6 of them died from cancer, heart failure or stroke during the second year of follow-up.

### 2.4 Statistical Analysis

Continuous variables with a normal distribution were presented as means with standard deviations. Continuous variables with a skewed distribution were presented as median values with interquartile ranges. Discrete variables were presented as frequencies and percentages. The chi square test was used to compare the differences between

---

**Table 2. Risk Assessment of VTE by the Caprini Model**

| Risk factors                                      | Score |
|---------------------------------------------------|-------|
| Stroke                                            |       |
| Multiple trauma                                   |       |
| Elective major lower extremity arthroplasty       | 5     |
| Hip, pelvic or leg fracture                       |       |
| Acute spinal cord injury (paralysis)              |       |
| Age (≥75)                                         |       |
| History of DVT or PTE                             |       |
| Positive Factor V Leiden                          |       |
| Positive prothrombin G20210A                      |       |
| Elevated serum homocysteine                       |       |
| Positive lupus anticoagulant                      | 3     |
| Other congenital or acquired thrombophilia        |       |
| Geparin-induced thrombocytopenia (HIT)            |       |
| Family history of VTE                             |       |
| Elevated anticardiolipin antibodies               |       |
| Age (61-74)                                       |       |
| Central venous access                             |       |
| Arthroscopic surgery                              |       |
| Major surgery                                     |       |
| Malignancy                                        | 2     |
| Laparoscopic procedure >45 min                    |       |
| Patient confined to bed                           |       |
| Immobilizing plaster cast                         |       |
| Age (41-60)                                       |       |
| Acute myocardial infarction                       |       |
| Heart failure                                     |       |
| Varicose veins                                    |       |
| Obesity (BMI>25)                                  |       |
| Inflammatory bowel disease                        |       |
| Sepsis                                            |       |
| COPD or abnormal pulmonary function              |       |
| Severe lung disease                               | 1     |
| Oral contraceptives or HRT                        |       |
| Pregnancy or postpartum                           |       |
| History of unexpected stillborn infant, recurrent spontaneous abortion (≥3), premature birth with toxemia or growth-restricted infant |       |
| Medical patient currently at bed rest             |       |
| Minor surgery planned                             |       |
| History of prior major surgery                    |       |
| Swollen legs                                      |       |
Caprini and Padua models in assessing the risks of VTE in hospitalized patients. Independent sample T test was used to compare the differences of VTE risk assessment among surgical and medical patients. Bilateral $p < 0.05$ was considered to be statistically significant.

### 3 Results

In total, 287 valid VTE cases were collected, including DVT and PTE symptoms. The clinical information of these VTE cases is shown in Table 3. Of the 287 VTE cases, 92 patients (32.1%) showed DVT symptoms, 93 patients (32.4%) showed PTE symptoms and 103 (35.9%) patients showed both DVT and PTE symptoms. The male to female ratio was about 1:1. The ages of the patients ranged from 20 to 99, with a median age of 66 and 114 of the patients (39.6%) were over 70 years old. Of the 287 VTE cases, 155 patients (54.0%) were from internal medicine departments, including respiratory, intensive care unit, cardiology, geriatrics, neurology, tumor, nephrology, infection, hematology, endocrinology, gastroenterology, and occupational disease; 133 patients (46.0%) were from surgery departments, including vascular surgery, obstetrics and gynecology, neurosurgery, general surgery, urinary surgery, thoracic surgery, ear, nose and throat, and orthopedics. We collected 190 valid data units of body mass index (BMI), ranging from 16 to 40 kg/m$^2$, with a median value of 25 kg/m$^2$. About 63% of patients had a BMI value over 25 kg/m$^2$.

The distribution of VTE risk factors based on the Caprini model is shown in Table 4. The most frequent risk factors included BMI $> 25$ kg/m$^2$ (120/190, 63.2%), medical patients currently at bed rest (136/287, 47.4%), and severe lung disease (132/287, 46.0%). The standard of elevated serum homocysteine levels was defined as 15 μmol/L, and 9 patients (50%) had elevated serum homocysteine levels out of 18 patients with valid data. For anticardiolipin antibody examination, 9 patients (13.4%) were positive among 67 cases with valid data. For protein C or protein S examination, 32 patients (52.4%) had protein C or protein S deficiency among 61 cases with valid data. Studies of Factor V Leiden, prothrombin G20210A and lupus anticoagulant were not performed.

For the Caprini model, most patients (95.5%) were classified as high risk (Figure 1A). For the Padua model, 109 patients (38.0%) were classified as low risk, while 178 patients (62.0%) were classified as high risk (Figure 1B). The percentage of high risk patients based on the Caprini model was significantly higher than that based on the Padua model (Table 5, $p < 0.0001$), which indicated that

| Table 3. Clinical Information of VTE Patients |
|---------------------------------------------|
| Clinical Index | Case Number | Percentage |
|----------------|-------------|------------|
| Symptom        |             |            |
| DVT            | 92          | 32.1%      |
| PTE            | 93          | 32.4%      |
| DVT and PTE    | 103         | 35.9%      |
| Total          | 287         | 100.0%     |
| Gender         |             |            |
| Male           | 141         | 49.1%      |
| Female         | 146         | 50.9%      |
| Total          | 287         | 100.0%     |
| Age            |             |            |
| 20–29          | 9           | 3.1%       |
| 30–39          | 14          | 4.9%       |
| 40–49          | 25          | 8.7%       |
| 50–59          | 49          | 17.1%      |
| 60–69          | 76          | 26.5%      |
| ≥70            | 114         | 39.7%      |
| Total          | 287         | 100.0%     |
| Department     |             |            |
| Internal medicine | 155       | 54.0%      |
| Respiratory    | 47          | 16.4%      |
| Intensive care unit | 15       | 5.2%       |
| Cardiology     | 15          | 5.2%       |
| Geriatrics     | 14          | 4.9%       |
| Neurology      | 11          | 3.8%       |
| Tumor          | 9           | 3.1%       |
| Nephrology     | 8           | 2.8%       |
| Infection      | 8           | 2.8%       |
| Hematology     | 8           | 2.8%       |
| Endocrinology  | 8           | 2.8%       |
| Gastroenterology | 6         | 2.1%       |
| Occupational disease | 6 | 2.1% |
| Surgery        | 131         | 45.6%      |
| Vascular surgery | 42          | 14.6%      |
| Obstetrics and Gynecology | 25 | 8.7% |
| Neurosurgery   | 12          | 4.2%       |
| General surgery | 11          | 3.8%       |
| Urinary surgery | 11         | 3.8%       |
| Thoracic surgery | 11        | 3.8%       |
| Ear, nose and throat | 11 | 3.8% |
| Orthopedics    | 9           | 3.1%       |
| Total          | 287         | 100.0%     |
| BMI            |             |            |
| < 25 kg/m$^2$  | 70          | 36.8%      |
| 25–28 kg/m$^2$ | 73          | 38.4%      |
| > 28 kg/m$^2$  | 47          | 24.7%      |
| Total          | 190         | 100.0%     |
the Caprini model was more effective in evaluating the VTE risks among hospitalized patients. Of the 287 VTE cases, 155 patients (54.0%) were from internal medicine departments, and 133 patients (46.0%) were from non-orthopedic surgery departments. In the Padua model, the average cumulative risk scores for internal medicine and surgery showed no significant differences (4.43±2.65 vs. 4.42±2.83, p = 0.962, Table 6). By contrast, in the Caprini model, the average cumulative risk score for surgery patients was significantly higher than internal medicine patients (7.84±3.45 vs. 6.68±3.27, p = 0.004, Table 7). These results indicate that the Caprini model was more effective in evaluating the VTE risks among surgery patients compared with internal medicine patients.

Among the 260 follow-up patients, 15 patients did not take any anticoagulant drugs after they were initially diagnosed as VTE; as well, 48 patients were diagnosed as recurrent VTE. The recurrence rate for high risk patients was 19.4% (48/247), while there was no recurrence among low or moderate risk patients (Figure 2). Of the 48 patients, 3 patients did not take any anticoagulant drugs after being initially diagnosed as VTE, while recurrent VTE occurred in 45 patients after they stopped the anticoagulant treatment.

**Figure 1** Risk levels of VTE Patients by the Caprini (A) and Padua (B) model

**Table 4. VTE Risk Factors of Patients in the Caprini Model**

| Factor                                                | Score | Case Number | Percentage |
|-------------------------------------------------------|-------|-------------|------------|
| Age (41~60)                                           | 1     | 84          | 29.3%      |
| Acute myocardial infarction                           | 1     | 4           | 1.4%       |
| Congestive heart failure                              | 1     | 68          | 23.7%      |
| Varicose veins                                        | 1     | 37          | 12.9%      |
| Obesity (BMI>25)&                                     | 1     | 120         | 63.2%      |
| Inflammatory bowel disease                            | 1     | 3           | 1.0%       |
| Sepsis (< 1 month)                                    | 1     | 6           | 2.1%       |
| COPD or abnormal pulmonary function                   | 1     | 106         | 36.9%      |
| Severe lung disease, including pneumonia (< 1 month)  | 1     | 132         | 46.0%      |
| Oral contraceptives or HRT                            | 1     | 2           | 0.7%       |
| Pregnancy or postpartum (< 1 month)                  | 1     | 2           | 0.7%       |
| History of unexpected stillborn infant,               | 1     | 16          | 5.6%       |
| recurrent spontaneous abortion (≤ 3), premature birth | 1     | 23          | 8.0%       |
| or growth-restricted infant                           |       |             |            |
| Medical patient currently at bed rest                 | 1     | 136         | 47.4%      |
| Minor surgery planned                                 | 1     | 10          | 3.5%       |
| History of prior major surgery (< 1 month)           | 1     | 39          | 13.6%      |
| Swollen legs                                          | 1     | 117         | 40.8%      |
| Age (61-74)                                           | 2     | 101         | 35.2%      |
| Central venous access                                 | 2     | 7           | 2.4%       |
| Arthroscopic surgery                                  | 2     | 0           | 0.0%       |
| Major surgery (> 45 min)                              | 2     | 20          | 7.0%       |
| Malignancy (past or present)                          | 2     | 80          | 27.9%      |
| Laparoscopic procedure (> 45 min)                     | 2     | 7           | 2.4%       |
| Patient confined to bed (> 72 h)                      | 2     | 39          | 13.6%      |
| Immobilizing plaster cast (< 1 month)                 | 2     | 1           | 0.3%       |
| Age ≥ 75                                              | 3     | 78          | 27.2%      |
| History of DVT or PTE                                 | 3     | 34          | 11.8%      |
| Positive Factor V Leiden; positive prothrombin        | 3     | 9           | 50.0%      |
| G20210A; positive lupus anticoagulant§                |       |             |            |
| Elevated serum homocysteine§                          | 3     | 9           | 50.0%      |
| Elevated anticardiolipin antibodies§                   | 3     | 9           | 13.4%      |
| Other congenital or acquired thrombophilia (protein C  | 3     | 32          | 52.4%      |
| or protein S deficiency)*                             |       |             |            |
| Heparin-induced thrombocytopenia (HIT)                 | 3     | 0           | 0.0%       |
| Family history of VTE                                 | 3     | 11          | 3.8%       |
| Stroke (< 1 month)                                    | 5     | 19          | 6.6%       |
| Acute spinal cord injury (paralysis) (< 1 month)      | 5     | 5           | 1.7%       |
| Multiple trauma (< 1 month)                           | 5     | 2           | 0.7%       |
| Hip, pelvic or leg fracture (< 1 month)               | 5     | 10          | 3.5%       |
| Elective major lower extremity arthroplasty           | 5     | 1           | 0.3%       |

*190 valid cases; §not performed yet; ‡18 valid cases; §67 valid cases; †61 valid cases.
Table 5. Number of VTE patients by risk level and cumulative score in two risk assessment models

| Risk grade          | Caprini model*, cases (%) | Padua model§, cases (%) | p# |
|---------------------|---------------------------|-------------------------|----|
| Low-moderate        | 13 (4.5)                  | 109 (38.0)              | <0.0001 |
| High                | 274 (95.5)                | 178 (62.0)              |    |
| Cumulative score, mean ± STD or median (interquartile range) | 7.21±3.40 | 4 (3-6) |    |

* For Caprini model, the risk levels were defined as follows: (1) Low risk (cumulative risk score 0-1); (2) Moderate risk (cumulative risk score 2); (3) High risk (cumulative risk score ≥3).
§ For Padua model, the risk levels were defined as follows: (1) Low risk (cumulative risk score 0-3); (2) High risk (cumulative risk score ≥4).
# chi square test

Table 6. Patients classified to different risk level in department of internal medicine and surgery by Padua Model

| Risk grade          | Internal medicine, cases (%) | Surgery, cases (%) | p |
|---------------------|-----------------------------|-------------------|---|
| Low risk (0-3)      | 56 (36.1)                   | 53 (40.2)         |   |
| High risk (≥4)      | 99 (63.9)                   | 79 (59.8)         |   |
| Cumulative score, mean ± STD | 4.43±2.65 | 4.42±2.83 | 0.962* |

* Independent sample T test

Table 7. Patients classified to different risk level in department of internal medicine and surgery by Caprini Model

| Risk grade          | Internal medicine, cases (%) | Surgery, cases (%) | p |
|---------------------|-----------------------------|-------------------|---|
| Low risk (0-1)      | 4 (2.6)                     | 1 (0.8)           |   |
| Moderate risk (2)   | 5 (3.2)                     | 3 (2.3)           |   |
| High risk (≥3)      | 146 (94.2)                  | 128 (96.9)        |   |
| Cumulative score, mean ± STD | 6.68±3.27 | 7.84±3.45 | 0.004* |

* Independent sample T test

Figure 2 Risk levels and recurrence of 260 follow-up patients by the Caprini model

4 Discussion

In this study, 287 VTE cases were collected within the Chinese population, and evaluated for risk factors using the Caprini and Padua models. Our results showed that the Caprini model was more effective in evaluating VTE risks in hospitalized patients compared with the Padua model, which is consistent with a previous study in the Chinese population [15]. The Caprini model includes over 40 risk factors, which provides more comprehensive and reasonable risk assessment than the Padua model.

Our results suggested that the Caprini model was more relevant in VTE risk assessment among surgery patients compared with internal medicine patients. Indeed, the Caprini model has been applied mainly to surgical patients, which may be due to the fact that this model contains more surgical factors [12, 13]. There has been limited research on the VTE risk assessment for medical inpatients so far. It was reported that the Padua model was effective in screening patients with high risk of VTE among medical inpatients [10]. However, the Padua model showed no significant difference in evaluating VTE risks between internal medicine and surgical patients in our studies.

In our studies, the most frequent risk factors of VTE included obesity, medical patients currently at bed rest, and severe lung disease. The ENDORSE study showed that obesity and long-term bed rest were two of the most common risk factors for VTE in surgical inpatients [20]. It was reported that obesity increased the risk of
recurrent VTE [21]. The sixth and seventh session of ACCP included obesity as the risk factor of DVT in orthopedics perioperative period. The mechanism of VTE formation in obese patients may be related to blood stasis. For patients in a long-term bed ridden state, the potential causes of VTE include slow flow velocity, local blood stasis, and high coagulation state.

Our results showed that severe pulmonary disease is another high risk factor of VTE occurrence. The incidence of PTE in patients with chronic obstructive pulmonary disease (COPD) ranged from 20% to 60%. It was regarded that the mechanism of VTE occurrence is mainly attributed to the pre-thrombosis state of COPD. In addition, the high blood coagulation state induced by long-term lying in bed and repeated infection may be one cause of increased VTE risk. The mechanism of VTE in patients with severe pulmonary disease remains to be further investigated.

Prothrombin (also called coagulation factor II) is proteolytically cleaved to form thrombin during the clotting process, which then catalyzes many coagulation-related reactions as a serine protease. Prothrombin G20210A is a genetic mutant associated with increased risk of VTE, and is mostly present in Caucasians [22]. Coagulation factor V is an important cofactor in the clotting process, which triggers coagulation by activating prothrombin. Factor V Leiden is the most common genetic hypercoagulability (prone to clotting) mutant in Caucasians, but can be rarely found in Asian and African populations [23, 24]. Therefore, we did not perform prothrombin G20210A and Factor V Leiden studies in the Chinese population. Lupus anticoagulant is an autoantibody which increases inappropriate blood clotting. Lupus anticoagulant testing was not performed in our studies due to limitation of experimental conditions. The association of Lupus anticoagulant and VTE in the Chinese population needs to be further investigated.

In conclusion, the Caprini and Padua models were used for risk assessment of VTE in the Chinese population. Our results indicated the Caprini model was more effective in evaluating VTE risks among hospitalized patients, especially for surgery patients. The most frequent risk factors included obesity, medical patients currently at bed rest and severe lung diseases. This study was limited by a relatively low sample size. In the future, more data need to be collected and studied to provide generalizable conclusions and to help determine the most suitable risk assessment model of VTE in the Chinese population.

**Conflict of interest:** Authors state no conflict of interest.

**References**

[1] Cohen A.T., Agnelli G., Anderson F.A., Arcelus J.I., Bergqvist D., Brecht J.G., et al., Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality, Thromb Haemost, 2007; 98, 756-764

[2] Heit J.A., Epidemiology of venous thromboembolism, Nat Rev Cardiol, 2015; 12, 464-474

[3] Heit J.A., Spencer F.A., White R.H., The epidemiology of venous thromboembolism, J Thromb Thrombolysis, 2016, 41, 3-14

[4] Kuroiwa M., Furuya H., Seo N., Kitaguchi K., Nakamura M., Sakuma M., et al., Incidence and clinical characteristics of perioperative pulmonary thromboembolism in Japan in 2008-results from the annual study of Japanese Society of Anesthesiologists, Committee on Patient Safety and Risk Management, Perioperative Pulmonary Thromboembolism Working Group, Masui, 2010, 59, 667-673

[5] WHO Guidelines for Safe Surgery 2009: Safe Surgery Saves Lives, Geneva, 2009

[6] Riley W.A., Cardiovascular risk assessment in individual patients from carotid intimal-medial thickness measurements, Curr Atheroscler Rep 2004, 6, 225-231

[7] Caprini J.A., Thrombosis risk assessment as a guide to quality patient care, Dis Mon 2005, 51, 70-78

[8] Cohen A.T., Alikhan R., Arcelus J.I., Bergmann J.F., Haas S., Merli G.J., et al., Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients, Thromb Haemost, 2005, 94, 750-759

[9] Kucher N., Koo S., Quiroz R., Cooper I.M., Paterno M.D., Soukonnikov B., et al., Electronic alerts to prevent venous thromboembolism among hospitalized patients, N Engl J Med 2005, 352, 969-977

[10] Barbar S., Noventa F., Rossetto V., Ferrari A., Brandolin B., Perlati M., et al., A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score, J Thromb Haemost, 2010, 8, 2450-2457

[11] Spyropoulos A.C., Anderson F.A., Fitzgerald G., Decousus H., Pini M., Chong B.H., et al., Predictive and associative models to identify hospitalized medical patients at risk for VTE, Chest 2011, 140, 706-714

[12] Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., et al., Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest 2012; 141, e278S-3255

[13] Gould M.K., Garcia D.A., Wren S.M., Karanicolos P.J., Arcelus J.I., et al., Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest 2012, 141, e2725-2775

[14] Pannucci C.J., Bailey S.H., Dreszer G., Fisher Wachtman C., Zumsteg J.W., Jaber R.M., et al., Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients, J Am Coll Surg 2011, 212, 105-112

[15] Zhou H., Wang L., Wu X., Tang Y., Yang J., Wang B., et al., Validation of a venous thromboembolism risk assessment
model in hospitalized Chinese patients: a case-control study, J Atheroscler Thromb, 2014, 21, 261-272

[16] Soomro Q., Yousuf N., Bhutto A.A., Abro H.A., Memon A.A., Venous thromboembolism (VTE): risk assessment in hospitalized patients, J Coll Physicians Surg Pak, 2014, 24, 455-458

[17] Hatef D.A., Kenkel J.M, Nguyen M.Q., Farkas J.P., Abtahi F., Rohrich R.J. et al., Thromboembolic risk assessment and the efficacy of enoxaparin prophylaxis in excisional body contouring surgery, Plast Reconstr Surg, 2008, 122, 269-279

[18] Samama M.M., Combe S., Conard J., Horellou MH., Risk assessment models for thromboprophylaxis of medical patients, Thromb Res, 2012, 129, 127-132

[19] Kahn S.R., Lim W., Dunn A.S., Cushman M., Dentali F., Akl E.A., et al., Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest 2012, 141, e195S-226S

[20] Cohen A.T., Tapson V.F., Bergmann J.F., Goldhaber S.Z., Kakkar A.K., Deslandes B., et al., Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study, Lancet 2008, 371, 387-394

[21] Kyrle P.A., Eichinger S., The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism, Wien Klin Wochenschr, 2003, 115, 471-474

[22] Rosendaal F.R., and Reitsma P.H., Genetics of venous thrombosis, J Thromb Haemost, 2009, 7 Suppl 1, 301-304

[23] Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al., Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature, 1994, 366, 66-71

[24] De Stefano V., Chiusolo P., Paciarotti K., Leone G., Epidemiology of factor V Leiden: clinical implications, Semin Thromb Hemost, 1998, 24, 367-379